Applied Genetic Technologies Corporation (AGTC) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Applied Genetic Technologies Corporation (AGTC) Healthcare & Pipeline Overview

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company specializing in the development of gene therapies for rare diseases. Their focus on ophthalmology and central nervous system disorders positions them in a high-growth, high-risk segment of the biotechnology industry, targeting unmet medical needs.

What Is the Investment Thesis for AGTC?

AGTC presents a high-risk, high-reward investment opportunity typical of clinical-stage biotechnology companies. The primary value driver is the successful completion of Phase 1/2 clinical trials for its lead ophthalmology programs, XLRP and achromatopsia. Positive data readouts could significantly increase the company's valuation. The advancement of preclinical programs in otology and CNS disorders represents further upside potential. However, the company's negative profit margin of -21976.6% underscores its reliance on external funding and the inherent risks of drug development. Investors should closely monitor clinical trial results, regulatory milestones, and the company's cash runway. The beta of 1.58 indicates higher volatility compared to the broader market.

Based on FMP financials and quantitative analysis

AGTC Key Highlights

• AGTC is a clinical-stage biotechnology company focused on gene therapies for rare diseases.
• The company's lead programs target X-linked retinitis pigmentosa (XLRP) and achromatopsia, both in Phase 1/2 clinical trials.
• AGTC has a gross margin of 100.0%, reflecting the nature of its early-stage revenue streams, primarily from collaborative agreements and grants.
• The company's profit margin is -21976.6%, indicative of substantial R&D expenses and the lack of commercial product revenue.
• AGTC has collaboration agreements with University of Florida, Bionic Sight, Inc., and Otonomy, Inc., leveraging external expertise.

Who Are AGTC's Competitors?

AGTC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AGTC's Key Strengths?

• Focus on rare diseases with high unmet medical needs.
• Advanced product candidates in Phase 1/2 clinical trials.
• Strong intellectual property portfolio.
• Collaborations with leading research institutions.

What Are AGTC's Weaknesses?

• Clinical-stage company with no commercial products.
• High R&D expenses and negative profit margin.
• Reliance on external funding.
• High dependence on clinical trial outcomes.

What Could Drive AGTC Stock Higher?

• Data readouts from Phase 1/2 clinical trials for XLRP program.
• Data readouts from Phase 1/2 clinical trials for achromatopsia program.
• Advancement of preclinical programs in otology and CNS disorders.
• Potential for new strategic partnerships and collaborations.

What Are the Key Risks for AGTC?

• Clinical trial failures could significantly impact the company's valuation.
• Regulatory hurdles and delays in approval process.
• Competition from other biotechnology companies developing gene therapies.
• Dependence on external funding and potential for dilution.
• Patent challenges and intellectual property disputes.

What Are the Growth Opportunities for AGTC?

• Advancement of XLRP Program: AGTC's X-linked retinitis pigmentosa (XLRP) program represents a significant growth opportunity. XLRP is a rare genetic eye disease that causes progressive vision loss in males. If the Phase 1/2 clinical trials are successful, AGTC could potentially capture a substantial share of the market for XLRP treatment, estimated to be worth hundreds of millions of dollars annually. The timeline for potential commercialization is dependent on clinical trial outcomes and regulatory approval, but could be within the next 3-5 years.
• Development of Achromatopsia Therapy: AGTC's achromatopsia program targets another rare genetic eye disorder characterized by impaired color vision and light sensitivity. Positive results from the ongoing Phase 1/2 clinical trials could lead to a valuable therapy for this underserved patient population. The market size for achromatopsia treatment is smaller than XLRP, but still represents a significant opportunity for AGTC. Commercialization could be possible within 5 years pending successful trial results.
• Expansion into Otology: AGTC's preclinical program in otology represents a diversification of its therapeutic focus. By developing gene therapies for hearing disorders, AGTC can tap into a large and growing market driven by aging populations and noise-induced hearing loss. The timeline for commercialization is longer than the ophthalmology programs, potentially 5-7 years, but the potential market size is substantial.
• Targeting Central Nervous System Disorders: AGTC's preclinical programs in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) offer long-term growth potential. These are devastating neurodegenerative diseases with limited treatment options. Successful development of gene therapies for FTD and ALS could position AGTC as a leader in the field. However, the development timeline is lengthy and the scientific challenges are significant.
• Strategic Partnerships and Collaborations: AGTC's existing collaborations with the University of Florida, Bionic Sight, Inc., and Otonomy, Inc., provide access to valuable expertise and resources. Expanding these partnerships and forging new collaborations with other research institutions and pharmaceutical companies can accelerate AGTC's research and development efforts and broaden its pipeline. These collaborations can also provide non-dilutive funding and reduce the company's financial risk.

What Opportunities Does AGTC Have?

• Successful completion of clinical trials and regulatory approval of lead product candidates.
• Expansion into new therapeutic areas, such as otology and CNS disorders.
• Strategic partnerships and collaborations.
• Advancements in gene therapy technology.

What Threats Does AGTC Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from other biotechnology companies.
• Patent challenges.
• Difficulty in raising capital.

What Are AGTC's Competitive Advantages?

• Intellectual property protection for its gene therapy technologies.
• Expertise in gene therapy development and manufacturing.
• Focus on rare diseases with limited competition.
• Collaborations with leading research institutions.

What Does AGTC Do?

Applied Genetic Technologies Corporation (AGTC) was founded in 1999 and is headquartered in Alachua, Florida. The company is dedicated to developing genetic therapies for patients suffering from rare and debilitating diseases. AGTC's primary focus is on ophthalmology, with advanced product candidates targeting X-linked retinitis pigmentosa (XLRP) and achromatopsia, both currently in Phase 1/2 clinical trials. Additionally, they are developing an optogenetic product candidate for advanced retinal disease. Beyond ophthalmology, AGTC has preclinical programs in otology, dry age-related macular degeneration, and central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. These diverse programs highlight AGTC's commitment to expanding the application of gene therapy to address a wide range of unmet medical needs. AGTC collaborates with institutions like the University of Florida, Bionic Sight, Inc., and Otonomy, Inc., leveraging external expertise to accelerate its research and development efforts. As a clinical-stage company, AGTC's value is heavily dependent on the success of its clinical trials and the eventual commercialization of its therapies.

What Products and Services Does AGTC Offer?

• Develop gene therapies for rare and debilitating diseases.
• Focus on ophthalmology, targeting X-linked retinitis pigmentosa (XLRP) and achromatopsia.
• Conduct Phase 1/2 clinical trials for lead product candidates.
• Develop an optogenetic product candidate for advanced retinal disease.
• Pursue preclinical programs in otology, dry age-related macular degeneration, and central nervous system disorders.
• Collaborate with universities and other biotechnology companies to advance research and development.

How Does AGTC Make Money?

• Develop and out-license gene therapy technologies.
• Generate revenue through research grants and collaborative agreements.
• Potentially generate revenue through commercial sales of approved therapies in the future.
• Focus on rare diseases with high unmet medical needs and potential for orphan drug designation.

What Industry Does AGTC Operate In?

AGTC operates within the biotechnology industry, a sector characterized by intense competition, high R&D costs, and significant regulatory hurdles. The market for gene therapies is rapidly expanding, driven by technological advancements and the increasing prevalence of genetic disorders. AGTC's focus on rare diseases positions it within a niche market with potentially high pricing power, but also limited patient populations. The company competes with larger pharmaceutical companies and specialized gene therapy firms, requiring a differentiated approach and strong intellectual property protection. Success hinges on clinical trial outcomes and the ability to navigate the complex regulatory landscape.

Who Are AGTC's Key Customers?

• Patients suffering from rare genetic diseases, particularly those affecting the eyes and central nervous system.
• Hospitals and clinics that treat patients with these diseases.
• Pharmaceutical companies that may license or acquire AGTC's technologies.
• Research institutions and government agencies that fund AGTC's research.

Net sellingInsider Activity

The most recent 12 insider filings for Applied Genetic Technologies Corporation break down as 12 sales and 0 purchases. On net that is roughly 163K shares disposed (about $0), a signal worth weighing alongside the fundamentals.

AGTC Valuation & Market Position

Relative to its peer group, AGTC's quantitative score of 50/100 is below the peer average of 75/100.

Company Profile

Applied Genetic Technologies Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Alachua, US. The company is led by CEO Susan Washer. AGTC has traded publicly since 2014.

AGTC Financials

AGTC Latest News

AGTC Analyst Consensus

AGTC MoonshotScore

What Investors Ask About Applied Genetic Technologies Corporation (AGTC) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources